Atalanta Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Atalanta Therapeutics's estimated annual revenue is currently $13M per year.
- Atalanta Therapeutics's estimated revenue per employee is $155,000
- Atalanta Therapeutics's total funding is $110M.
Employee Data
- Atalanta Therapeutics has 84 Employees.
- Atalanta Therapeutics grew their employee count by 18% last year.
Atalanta Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | General Counsel | Reveal Email/Phone |
2 | SVP | Reveal Email/Phone |
3 | VP, Head in vivo Pharmacology | Reveal Email/Phone |
4 | VP Human Resources | Reveal Email/Phone |
5 | VP Biochemistry & Pharmacology, In Vitro Biology | Reveal Email/Phone |
6 | VP, Chemistry | Reveal Email/Phone |
7 | VP, Head Neuroscience | Reveal Email/Phone |
8 | Senior Director, Controller | Reveal Email/Phone |
9 | Sr. Director, Research | Reveal Email/Phone |
10 | Chief Scientific Officer | Reveal Email/Phone |
Atalanta Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Atalanta Therapeutics?
We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. We are headquartered in Boston, Mass.
keywords:N/A
$110M
Total Funding
84
Number of Employees
$13M
Revenue (est)
18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Atalanta Therapeutics News
Atalanta Therapeutics Appoints Alfred Sandrock to Board of Directors Business Wire
Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding. The financing was provided exclusively by F-Prime Capital. Additionally, Atalanta announced strategic collaborations with Biogen (N ...
Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding. The financing was provided exclusively by F-Prime Capital. Additionally, Atalanta announced strategic collaborations with Biogen (N ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $21M | 84 | 22% | N/A |
#2 | $10.9M | 84 | -38% | $32M |
#3 | $15M | 84 | 1% | N/A |
#4 | $27.1M | 84 | -20% | N/A |
#5 | $12.2M | 84 | -36% | $67.4M |